Blocking Pyk2 to both build bone and reduce bone breakdown
Uncovering the dual anabolic and anti-catabolic effects of Pyk2 inhibition on bone mass
Researchers are looking at whether blocking a protein called Pyk2 can help bones rebuild and slow bone loss for people with age- or menopause-related bone thinning.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11139526 on NIH RePORTER |
What this research studies
This work uses mouse models and lab-grown bone cells to see how turning off Pyk2 changes bone-building cells (osteoblasts) and bone-resorbing cells (osteoclasts). The team models menopause by removing ovarian hormones in mice and tests how Pyk2 loss interacts with estrogen and common bone drugs. They measure bone mass, bone strength, and cell activity to see if a single approach can both increase bone formation and reduce breakdown. Findings will guide whether drugs that block Pyk2 could be developed for people with age- or menopause-related bone loss.
Who could benefit from this research
Good fit: People with age-related or postmenopausal bone loss or osteoporosis would be the most likely future candidates for therapies emerging from this work.
Not a fit: Patients whose bone problems come from unrelated causes (for example certain genetic bone disorders, active cancer affecting bone, or infections) may not benefit from a Pyk2-targeted approach.
Why it matters
Potential benefit: If successful, blocking Pyk2 could lead to a new therapy that both increases bone mass and reduces bone breakdown, potentially improving bone strength with fewer side effects than current options.
How similar studies have performed: Preclinical mouse and cell experiments already suggest Pyk2 loss boosts bone formation and reduces resorption, but translating this to a human treatment has not yet been done.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Bruzzaniti, Angela — Indiana University Indianapolis
- Study coordinator: Bruzzaniti, Angela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.